Evidence map›Paper›PMID 34849326›Full record

ArticleNetwork modeling and analysis in health informatics and bioinformatics2021

In-silico design of a multi-epitope for developing sero-diagnosis detection of SARS-CoV-2 using spike glycoprotein and nucleocapsid antigens.

Amirreza Javadi Mamaghani, Zahra Arab-Mazar, Siamak Heidarzadeh, Mohammad Mehdi Ranjbar, Shima Molazadeh, Sama Rashidi, Farzad Niazpour, Mohadeseh Naghi Vishteh, Homayoon Bashiri, Arezoo Bozorgomid and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Network modeling and analysis in health informatics and bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Amirreza Javadi MamaghaniDepartment of Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra Arab-MazarDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Siamak HeidarzadehDepartment of Microbiology and Virology, Zanjan University of Medical Sciences, Zanjan, Iran.
Mohammad Mehdi RanjbarRazi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
Shima MolazadehDepartment of Pathobiology, Faculty of Veterinary Medicine, Science and Research Branch, Olom Tahghighat Islamic Azad University, Tehran, Iran.
Sama RashidiDepartment of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Farzad NiazpourFaculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran.
Mohadeseh Naghi VishtehDepartment of Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Homayoon BashiriInfectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Arezoo BozorgomidInfectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Hamed BehniafarDepartment of Medical Parasitology, Sarab Faculty of Medical Sciences, Sarab, Iran.
Mohammad AshrafiFaculty of Medicine, Islamic Azad University, Qom, Iran.
Kermanshah University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRIslamic Azad University, Science and Research Branch · IRQom Islamic Azad University · IRRazi Vaccine and Serum Research Institute · IRShiraz University of Medical Sciences · IRTehran University of Medical Sciences · IRUniversity of Tabriz · IRZanjan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a pandemic disease caused by novel corona virus, SARS-CoV-2, initially originated from China. In response to this serious life-threatening disease, designing and developing more accurate and sensitive tests are crucial. The aim of this study is designing a multi-epitope of spike and nucleocapsid antigens of COVID-19 virus by bioinformatics methods. The sequences of nucleotides obtained from the NCBI Nucleotide Database. Transmembrane structures of proteins were predicted by TMHMM Server and the prediction of signal peptide of proteins was performed by Signal P Server. B-cell epitopes' prediction was performed by the online prediction server of IEDB server. Beta turn structure of linear epitopes was also performed using the IEDB server. Conformational epitope prediction was performed using the CBTOPE and eventually, eight antigenic epitopes with high physicochemical properties were selected, and then, all eight epitopes were blasted using the NCBI website. The analyses revealed that α-helices, extended strands, β-turns, and random coils were 28.59%, 23.25%, 3.38%, and 44.78% for S protein, 21.24%, 16.71%, 6.92%, and 55.13% for N Protein, respectively. The S and N protein three-dimensional structure was predicted using the prediction I-TASSER server. In the current study, bioinformatics tools were used to design a multi-epitope peptide based on the type of antigen and its physiochemical properties and SVM method (Machine Learning) to design multi-epitopes that have a high avidity against SARS-CoV-2 antibodies to detect infections by COVID-19.

Indexed as

Multi-epitopesNucleocapsid phosphoproteinSARS-CoV2Serological testsSpike glycoprotein

Identifiers

PMID34849326
PMCPMC8614630
OpenAlexW3217683774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.